
Tele-pulmonary rehabilitation: global expert perspectives on unresolved issues
Pulmonary rehabilitation (PR) is a multidisciplinary intervention whose cornerstone is aerobic and resistive exercise training coupled with disease education. Advances in the field of PR have focused on remote delivery to address access to this guideline-driven intervention. A scientific symposium on key unresolved issues facing tele-PR was programmed at the 2025 American Thoracic Society International Conference. This narrative review summarizes presentations by PR experts on synchronous versus asynchronous delivery modes; exercise training using aerobic gym equipment versus minimal equipment; and the primary functional outcome being a measure of exercise capacity versus measures of frailty or physical activity. While synchronous tele-PR may enhance safety, allow real-time feedback during exercise, and foster group camaraderie, asynchronous delivery offers flexibility and individualized engagement with clinicians. Gym equipment may facilitate higher exercise intensity training and progression, but the experienced PR clinician can achieve both with minimal equipment and a clear prescription for ground walking speed, walking duration, or weight additions. Finally, improvement in exercise capacity is a well-established outcome of PR, yet evidence is variable as to whether this benefit translates into increased physical activity. It will be important to study the concept of frailty to individualize program content. All PR models must provide the core components and lead to the expected outcomes. New tele-PR models must be rigorously evaluated. The goal is to provide equitable access to effective PR to as many people with chronic lung disease as possible. Tele-PR has the potential to improve access, but should not replace center-based PR.
Target Audience
Pulmonologists, critical care specialists, translational researchers, and clinicians.
Learning Objectives
- Distinguish the evidence for center-based pulmonary rehabilitation from that for virtual pulmonary rehabilitation.
- Identify key issues that must be resolved before pulmonary rehabilitation can be delivered completely virtually.
- Describe methods and strategies needed for remotely delivered pulmonary rehabilitation programs to maintain the core components of center-based pulmonary rehabilitation.
Course summary
- 1.00 AMA PRA Category 1 Credit(s)™
The American Thoracic Society designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Participation
This section is not in use.
Please visit the Accreditation tab to view Accreditation and Disclosure information.
Accreditation Statement
The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Disclosure Declaration
Article Authorship Disclosures (as submitted to the ATS prior to article publication date):
Marilyn L. Moy, (Pulmonary and Critical Care Medicine Section, VA Boston Healthcare System and Harvard Medical School, Boston, MA, USA) reported grants or contracts with the following: The VA Research Enhancement Award Program (REAP):REhabilitation Promoting Prevention And Improved Resilience (REPPAIR) VA Rehabilitation Research and Development I50 RX003430 and Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease NIH/NHLBI UG3/UH3. Dr Moy is the Site Principal Investigator of the following: The Effect of a Technology-Mediated Integrated Walking and Tai Chi Intervention on Physical Function in Veterans with COPD and Chronic Musculoskeletal Pain VA Rehabilitation Research and Development VA Merit Award I01 RX004225 and Mindful Steps: A Web-Based Mind-Body Exercise Intervention to Promote Physical Activity in Chronic Cardiopulmonary Disease NIH/NCCIH R01 AT012166. Dr Moy has received honorarium for speaking at Grand Rounds at the University of Buffalo (virtual). Dr Moy is a Member of DSMB for National Heart Lung and Blood Institute (NHLBI) funded multi-site trial of physical activity monitoring in Pulmonary Hypertension at the University of Pennsylvania, Philadelphia, PA and Member of DSMB for NHLBI funded trial “Optimizing Effectiveness and Implementation of COPD Self-Management Treatment” (R01 HL173120) at Rush University Medical Center, Chicago, IL.
Jennifer A. Alison, (Sydney School of Health Sciences, The University of Sydney, New South Wales, Australia) reported grants from the following Cardiovascular Research Capacity Programs: Aboriginal Heart Health Grants 2025, NSW Government AUD 250,000 money to institution; NSW Cardiovascular Research Capacity Program Grant. 2024 AUD 449,463 money to institution; Physiotherapy Research Foundation Australia Grant AUD 10,000 money to institution; Medical Research Futures Fund Grant 2024-2028, Australian Government AUD 1,629,440; Dr. Allison reported support for attending the Australian Physiotherapy Scientific Conference 2025. Dr. Allison is a Data Safety and Monitoring Board member for: Targeting Treatable Traits in COPD to prevent hospitalizations (TERRACOTTA) trial.
Richard Casaburi (Respiratory Research Center, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA) reported no relevant financial relationships with ineligible companies.
Narelle S. Cox, (Respiratory Research@Alfred, School of Translational Medicine, Monash University and Institute for Breathing and Sleep, Melbourne, Victoria, Australia) reported Fellowship funding from National Health and Medical Research Council (NHRMC)(GNT2016286).
Christopher Mosher, (Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC, USA) reported grants or contracts from the following: NIH GEMSSTAR Award (1R03-AG082878-01) Institute RofLumilast or Azithromycin to prevent COPD Exacerbations (RELIANCE) (PCORI funded) Institute; NIH K76: Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations (INSPIRE-COPD-E) Institute; A Phase III, Multicentre, Randomised, Double-blind, Chronic Dosing, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 (AstraZeneca) Institute; Blueprint-COPD: Coping skills support for patients with comorbid COPD and anxiety or depression (ALA funded) Institute; NHLBI: Accuracy and Precision in CT Quantification of COPD Through Virtual Imaging Trials Institute; Seabreeze STAT COPD (Connect Biopharma LLC) Institute; STRIDE Registry (Sanofi & Regeneron) Institute; Genetic Epidemiology of COPD (COPDGene) (NIH) Institute; Consulting fees from: COPD Foundation Self, International Consulting Associates, Inc. Self, Guidepoint Global, LLC Self, Physicians Education Resources, LLC Self, Wellinks Self, Genentech Self, Onviv Self, GSK Self; Dr. Mosher reported payment from Respiratory Care Foundation and meeting attendance support from the following: American Lung Association Self, COPDgene Self, NIH GEMSSTAR Award (1R03-AG082878-01) Self, NIH K76: Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD, Exacerbations (INSPIRE-COPD-E), Dr. Mosher reported being on a data safety board with Wellinks.
Carolyn L. Rochester, (Section of Pulmonary, Critical Care Medicine, Yale School of Medicine, New Haven, CT, USA and VA Connecticut Healthcare System, West Haven, CT, USA) reported consulting fees from the following: Sanofi Pharmaceuticals Member, COPD Advisory Board, personal payment; Regeneron Pharmaceuticals Member, COPD Advisory Board, personal payment; Astra-Zeneca Pharmaceuticals Member, COPD Advisory Board, personal payment; Astra-Zeneca Pharmaceuticals Member, Steering Committee QUEST quality improvement initiative; Boehringer-Ingelheim Pharmaceuticals Member, COPD Advisory Board, personal payment; Astra-Zeneca Pharmaceuticals Past co-investigator on COPD-related clinical trial, no direct funds received; Dr. Rochester is a member of the ATS Quality Improvement and Implementation Committee.
Thierry Troosters, (Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC, USA) reported a grant or contract from the following C2M/24/075; Validation and use of surface EMG as a biomarker for skeletal muscle fatigue in people with COPD; Internal grant KU Leuven 700k.
Linda Nici, (Pulmonary and Critical Care Medicine Section, VA Providence Healthcare System and The Warren Alpert Medical School of Brown University, Providence, RI, USA) reported no relevant financial relationships with ineligible companies.
AnnalsATS CME Planners
Margaret M. Hayes, M.D., (Harvard Medical School, Boston, MA, USA) reported receiving payments as an author for a chapter on heliox for UpToDate.
Caroline Okorie, M.D., M.P.H., (Stanford University School of Medicine, Stanford, CA, USA) reported no financial relationships with ineligible companies.
Off-Label Usage Disclosure
All relevant financial relationships have been reviewed and mitigated.
Instructions to Receive Credit
To receive credit for this journal article:
- Read the journal article. Keep track of how long it takes you to read it.
- Once you open the article, the Post-Test becomes available. After reading the article, answer the post-test questions. You must answer all questions correctly to earn credit. You may take the test as many times as you like.
- Once you pass the Post-Test, the Evaluation becomes available. Answer all the evaluation questions.
- Once you complete the evaluation, select the amount of credit to receive based on the time it took you to read the article.
- You can view, save and print your Certificate by pressing the Certificate button.
- To review the credits you've earned in this system and reprint certificates, go to the My Learning drop-down list. Then select Transcript.
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™
The American Thoracic Society designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Participation
Price
To start this learning activity, press the Take Activity button. Then follow the on-screen instructions.
The system keeps track of your progress. If you close the activity and resume it later, it will re-start where you left off.

Facebook
X
LinkedIn
Forward